YH 34160
Alternative Names: YH-34160; YHC-2110Latest Information Update: 08 Jan 2023
At a glance
- Originator Yuhan; Yuhan ANZ
- Class Cytokines; Obesity therapies; Recombinant fusion proteins; Transforming growth factors
- Mechanism of Action Growth differentiation factor 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
- Research Non-alcoholic steatohepatitis
Most Recent Events
- 13 Dec 2022 Early research in Non-alcoholic steatohepatitis in Australia (unspecified route) (Yuhan ANZ pipeline, December 2022)
- 13 Dec 2022 Early research in Obesity in Australia (SC) (Yuhan ANZ pipeline, December 2022)
- 03 Jun 2022 Pharmacodynamics data from a preclinical study in Obesity presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)